Directing patients selectively to centers performing higher volumes of ventricular tachycardia (VT) ablation may help reduce in-hospital complications following the procedure, an observational study ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced ...

BERLIN, Germany—Treatment of monomorphic ventricular tachycardia (VT) with a novel ultralow-temperature cryoablation catheter (vCLAS; Adagio Medical) appears to be safe and effective in patients with ...

A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular tachycardia (VT) in 94% of patients. The late-breaking science is presented at EHRA 2024, a ...

LAGUNA HILLS, Calif., Sept. 13, 2023 /PRNewswire/ -- Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), ...

For ventricular tachycardia (VT), catheter ablation is often seen as an option of last resort, however, some are questioning whether there has been too much emphasis on antiarrhythmic medication. In ...

Most biotechs savour the moment when they chalk up their first sales, but Imricor Medical Systems (ASX:IMR) founder and CEO Steve Wedan almost regrets the company is generating small initial revenues ...